Health status in the TORCH study of COPD: treatment efficacy and other determinants of changeReport as inadecuate

Health status in the TORCH study of COPD: treatment efficacy and other determinants of change - Download this document for free, or read online. Document in PDF available to download.

Respiratory Research

, 12:71

First Online: 01 December 2011Received: 09 February 2011Accepted: 31 May 2011


BackgroundLittle is known about factors that determine health status decline in clinical trials of COPD.

ObjectivesTo examine health status changes over 3 years in the TORCH study of salmeterol+fluticasone propionate SFC vs. salmeterol alone, fluticasone propionate alone or placebo.

MethodsSt George-s Respiratory Questionnaire SGRQ was administered at baseline then every 6 months.

Measurements and Main ResultsData from 4951 patients in 28 countries were available. SFC produced significant improvements over placebo in all three SGRQ domains during the study: Symptoms -3.6 95% CI -4.8 -2.4, Activity -2.8 95% CI -3.9 -1.6, Impacts -3.2 95% CI -4.3 -2.1 but the pattern of change over time differed between domains. SGRQ deteriorated faster in patients with Global Initiative for Chronic Obstructive Lung Disease GOLD stages III and IV relative to GOLD stage II p < 0.001. There was no difference in the relationship between deterioration in SGRQ Total score and forced expiratory volume in one second FEV1 decline as % predicted in men and women. Significantly faster deterioration in Total score relative to FEV1 % predicted was seen in older patients ≥ 65 years and there was an age-related change in Total score that was independent of change in FEV1. The relationship between deterioration in FEV1 and SGRQ did not differ in different world regions, but patients in Asia-Pacific showed a large improvement in score that was unrelated to FEV1 change.

ConclusionsIn addition to treatment effects, health status changes in clinical trials may be influenced by demographic and disease-related factors. Deterioration in health status appears to be fastest in older persons and those with severe airflow limitation.

Trial NCT00268216

KeywordsCOPD quality of life health status lung function Electronic supplementary materialThe online version of this article doi:10.1186-1465-9921-12-71 contains supplementary material, which is available to authorized users.

Download fulltext PDF



Related documents